Read More

Dyadic Announces Research And Development Collaboration Agreement With Global Biopharmaceutical Company To Design And Produce Recombinant Proteins Using Dyadic’s C1 Filamentous Fungal Based Microbial Protein Production Platform

Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option

DYAI